Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.

Tom EwenAkhtar HusainNiki StefanosPaul BarrettClaire JonesTom NessAnna LongStuart HorswellHelen BosomworthJoe LowensteinGrant RichardsonDavid SwanAshleigh McConnellAidan RoseTom AndrewNick ReynoldsJosep MalvehyChristina CarreraLlucia AlsoSonia MailerTom HelmLiang DingPaul BognerSebastian PodlipnikSusana Puig SardàGrant A McArthurGyorgy ParaghMarie LabusPhilip SloanJane L ArmstrongPenny E Lovat

Published in: The British journal of dermatology (2023)

These data provide further evidence validating AMBLor as a prognostic biomarker to identify non-ulcerated AJCC stage I and II melanoma tumours at low risk of disease recurrence.

Keyphrases

skin cancer
electronic health record
big data
machine learning
wound healing
artificial intelligence